Investigate a Pharmacokinetic Characteristics and the Safety of AG1502 in Healthy Male Subjects

NCT02614352 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2015-11-25

No results posted yet for this study

Summary

Primary object : Evaluate pharmacokinetic property AG1502 and Candesartan 32mg and Atorvastatin 40mg in healthy male subjects.

Conditions

  • Healthy Male Subjects

Interventions

DRUG

Atorvastatin + Candesartan

DRUG

AG1502

Sponsors & Collaborators

  • Ahn-Gook Pharmaceuticals Co.,Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2016-02-29

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02614352 on ClinicalTrials.gov